1
|
Yaghi S, Shu L, Mandel DM, Leon Guerrero CR, Henninger N, Muppa J, Affan M, Ul Haq Lodhi O, Heldner MR, Antonenko K, Seiffge DJ, Arnold M, Salehi Omran S, Crandall RC, Lester E, Lopez Mena D, Arauz A, Nehme A, Boulanger M, Touzé E, Sousa JA, Sargento-Freitas J, Barata V, Castro-Chaves P, Brito MTÁP, Khan M, Mallick D, Rothstein A, Khazaal O, Kaufmann J, Engelter ST, Traenka C, Aguiar de Sousa D, Soares M, Rosa SD, Zhou LW, Gandhi P, Field TS, Mancini S, Metanis I, Leker RR, Pan K, Dantu V, Baumgartner KV, Burton TM, Freiin von Rennenberg R, Nolte CH, Choi RK, MacDonald JA, Bavarsad Shahripour R, Guo X, Ghannam M, AlMajali M, Samaniego EA, Sanchez S, Rioux B, Zine-Eddine F, Poppe AY, Fonseca AC, Baptista M, Cruz D, Romoli M, De Marco G, Longoni M, Keser Z, Griffin KJ, Kuohn L, Frontera JA, Amar J, Giles JA, Zedde M, Pascarella R, Grisendi I, Nzwalo H, Liebeskind DS, Molaie AM, Cavalier A, Kam W, Mac Grory B, Al Kasab S, Anadani M, Kicielinski KP, Eltatawy AR, Chervak LM, Chulluncuy-Rivas R, Aziz YN, Bakradze E, Tran TL, Rodrigo-Gisbert M, Requena M, Saleh Velez FG, Ortiz Garcia JG, Muddasani V, de Havenon A, Vishnu VY, Yaddanapudi SS, Adams L, Browngoehl A, Ranasinghe T, Dunston R, Lynch Z, Penckofer M, Siegler JE, Mayer SV, Willey JZ, Zubair AS, Cheng YK, Sharma R, Marto JP, Mendes Ferreira V, Klein P, Nguyen TN, Asad SD, Sarwat Z, Balabhadra A, Patel S, Secchi TL, Martins SC, Mantovani GP, Kim YD, Krishnaiah B, Elangovan C, Lingam S, Qureshi AY, Fridman S, Alvarado-Bolaños A, Khasiyev F, Linares G, Mannino M, Terruso V, Vassilopoulou S, Tentolouris-Piperas V, Martínez-Marino M, Carrasco Wall VA, Indraswari F, El Jamal S, Liu S, Alvi M, Ali F, Sarvath MM, Morsi RZ, Kass-Hout T, Shi F, Zhang J, Sokhi D, Said J, Simpkins AN, Gomez R, Sen S, Ghani MR, Elnazeir M, Xiao H, Kala NS, Khan F, Stretz C, Mohammadzadeh N, Goldstein ED, Furie KL. Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study. Stroke 2024. [PMID: 38335240 DOI: 10.1161/strokeaha.123.045731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2024]
Abstract
Background: Small, randomized trials of cervical artery dissection (CAD) patients showed conflicting results regarding optimal stroke prevention strategies. We aimed to compare outcomes in patients with CAD treated with antiplatelets versus anticoagulation. Methods: This is a multi-center observational retrospective international study (16 countries, 63 sites) that included CAD patients without major trauma. The exposure was antithrombotic treatment type (anticoagulation vs. antiplatelets) and outcomes were subsequent ischemic stroke and major hemorrhage (intracranial or extracranial hemorrhage). We used adjusted Cox regression with Inverse Probability of Treatment Weighting (IPTW) to determine associations between anticoagulation and study outcomes within 30 and 180 days. The main analysis used an "as treated" cross-over approach and only included outcomes occurring on the above treatments. Results: The study included 3,636 patients [402 (11.1%) received exclusively anticoagulation and 2,453 (67.5%) received exclusively antiplatelets]. By day 180, there were 162 new ischemic strokes (4.4%) and 28 major hemorrhages (0.8%); 87.0% of ischemic strokes occurred by day 30. In adjusted Cox regression with IPTW, compared to antiplatelet therapy, anticoagulation was associated with a non-significantly lower risk of subsequent ischemic stroke by day 30 (adjusted HR 0.71 95% CI 0.45-1.12, p=0.145) and by day 180 (adjusted HR 0.80 95% CI 0.28-2.24, p=0.670). Anticoagulation therapy was not associated with a higher risk of major hemorrhage by day 30 (adjusted HR 1.39 95% CI 0.35-5.45, p=0.637) but was by day 180 (adjusted HR 5.56 95% CI 1.53-20.13, p=0.009). In interaction analyses, patients with occlusive dissection had significantly lower ischemic stroke risk with anticoagulation (adjusted HR 0.40 95% CI 0.18-0.88) (Pinteraction=0.009). Conclusions: Our study does not rule out a benefit of anticoagulation in reducing ischemic stroke risk, particularly in patients with occlusive dissection. If anticoagulation is chosen, it seems reasonable to switch to antiplatelet therapy before 180 days to lower the risk of major bleeding. Large prospective studies are needed to validate our findings.
Collapse
Affiliation(s)
- Shadi Yaghi
- Neurology, Alpert Medical School at Brown University, UNITED STATES
| | - Liqi Shu
- Neurology, Alpert Medical School of Brown University, UNITED STATES
| | - Daniel M Mandel
- Neurology, University of Miami Miller School of Medicine, UNITED STATES
| | | | - Nils Henninger
- Departments of Neurology and Psychiatry, University of Massachusetts Medical School, UNITED STATES
| | | | | | | | - Mirjam R Heldner
- Department of Neurology, Inselspital, University Hospital and University of Bern, SWITZERLAND
| | - Kateryna Antonenko
- Department of Neurology, Inselspital, University Hospital and University of Bern, Bern, Switzerland, SWITZERLAND
| | - David J Seiffge
- Neurology, Inselspital, Bern University Hospital, University of Bern, SWITZERLAND
| | - Marcel Arnold
- Department of Neurology, University hospital of Bern, SWITZERLAND
| | | | | | | | - Diego Lopez Mena
- National Institute of Neurology and Neurosurgery of Mexico, MEXICO
| | - Antonio Arauz
- stroke clinic, Instituto Nacional de Neurologia, MEXICO
| | | | - Marion Boulanger
- Service de neurologie,, Universite Caen Normandie, CHU Caen Normandie, INSERM U1237, CYCERON, boulevard Henri Becquerel, Caen, France, Blood and Brain @ Caen-Normandie Institute (BB@C), Caen, France, FRANCE
| | | | | | | | | | | | | | - Muhib Khan
- Department of Neurology, Mayo Clinic, UNITED STATES
| | | | - Aaron Rothstein
- Department of Neurology, University of Pennsylvania, UNITED STATES
| | - Ossama Khazaal
- Department of Neurology, University of Pennsylvania, UNITED STATES
| | | | | | - Christopher Traenka
- Department of Neurology and Stroke Center, University Hospital Basel, SWITZERLAND
| | | | - Mafalda Soares
- Lisbon Central University Hospital, University of Lisbon, PORTUGAL
| | - Sara Db Rosa
- Neuroradiology, Lisbon Central University Hospital, PORTUGAL
| | - Lily W Zhou
- Neurology, The University of British Columbia, CANADA
| | | | - Thalia S Field
- Centre for Brain Health, Division of Neurology, Vancouver Stroke Program, University of British Columbia, CANADA
| | | | - Issa Metanis
- Hebrew University-Hadassah Medical Center, ISRAEL
| | - Ronen R Leker
- Neurology, Hadassah-Hebrew University Medical Center, ISRAEL
| | - Kelly Pan
- Rhode Island Hospital, UNITED STATES
| | - Vishnu Dantu
- Barrow Neurological Institute - St. Joseph's Hospital and Medical Center, UNITED STATES
| | | | - Tina M Burton
- Neurology, The Warren Alpert Medical School of Brown University, UNITED STATES
| | - Regina Freiin von Rennenberg
- Department of Neurology (Klinik und Hochschulambulanz für Neurologie), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
| | | | | | | | - Reza Bavarsad Shahripour
- University of California San Diego Comprehensive Stroke Center, Department of Neurosciences, University of California, San Diego, USA., UNITED STATES
| | - Xiaofan Guo
- Neurology, Department of Neurology, Loma Linda University Health, UNITED STATES
| | - Malik Ghannam
- Neurology, University of Iowa Hospitals and Clinics, UNITED STATES
| | | | - Edgar A Samaniego
- Neurology, Neurosurgery & Radiology, University of Iowa, UNITED STATES
| | | | | | | | | | - Ana Catarina Fonseca
- Department of Neurosciences and Mental Health (Neurology), University of Lisbon, PORTUGAL
| | - Maria Baptista
- Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto
| | - Diana Cruz
- Neurology, Hospital Santa Maria - CHULN, PORTUGAL
| | | | - Giovanna De Marco
- Neurology and Stroke Unit, Department of Neuroscience,, Bufalini Hospital, ITALY
| | | | | | | | - Lindsey Kuohn
- Department of Neurology, NYU Langone Health, UNITED STATES
| | | | - Jordan Amar
- Keck School of Medicine of the University of Southern California, UNITED STATES
| | - James A Giles
- Neurology, Yale University School of Medicine, UNITED STATES
| | - Marialuisa Zedde
- Neurology Unit, Stroke Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia
| | | | - Ilaria Grisendi
- Neuromotor physiology, Azienda USL-IRCCS di Reggio Emilia, ITALY
| | - Hipólito Nzwalo
- Ageing and Cerebrovascular Research Group, Algarve Biomedical Research Institute, PORTUGAL
| | - David S Liebeskind
- Neurovascular Imaging Research Core & Neurology, University of California, Los Angeles, UNITED STATES
| | - Amir M Molaie
- Neurology, University of California at Los Angeles Medical Center, UNITED STATES
| | - Annie Cavalier
- Neurology, Duke University School of Medicine, UNITED STATES
| | - Wayneho Kam
- Duke University Hospital; UNC Health Rex Comprehensive Stroke Center, UNITED STATES
| | - Brian Mac Grory
- Neurology, Duke University School of Medicine, UNITED STATES
| | - Sami Al Kasab
- Neurosurgery and Neurology, Medical University of south Carolina, UNITED STATES
| | - Mohammad Anadani
- Neurology, Medical University of South Carolina, College of Medicine, UNITED STATES
| | | | | | - Lina M Chervak
- Department of Neurology, University of Cincinnati Medical Center, UNITED STATES
| | | | - Yasmin Ninette Aziz
- Neurology and Rehabilitation Medicine, University of Cincinnati, UNITED STATES
| | | | | | - Marc Rodrigo-Gisbert
- Hospital Universitari Vall d'Hebron. Departament de Medicina, Universitat Autònoma de Barcelona. Barcelona. Spain
| | - Manuel Requena
- Neurology. Universitat Autònoma de Barcelona, Univ Hosp Vall d'Hebron, SPAIN
| | - Faddi Ghassan Saleh Velez
- Department of Neurology, Vascular Division, The University of Oklahoma Health Sciences Center, UNITED STATES
| | - Jorge G Ortiz Garcia
- Department of Neurology, Division of Critical Care Neurology, Division of Stroke and Cerebrovascular Disorders, The University of Oklahoma Health Sciences Center, UNITED STATES
| | | | - Adam de Havenon
- Department of Neurology, Yale University School of Medicine, UNITED STATES
| | | | | | | | | | | | - Randy Dunston
- Wake Forest University Baptist Medical Center, UNITED STATES
| | | | - Mary Penckofer
- Cooper Medical School of Rowan University, UNITED STATES
| | - James E Siegler
- Department of Neurology, University of Chicago, UNITED STATES
| | | | | | | | | | | | - João Pedro Marto
- Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, PORTUGAL
| | | | - Piers Klein
- Neurology, Boston University Chobanian & Avedisian School of Medicine, UNITED STATES
| | - Thanh N Nguyen
- Neurology, Radiology, Boston University Chobanian and Avedisian School of Medicine, UNITED STATES
| | | | | | - Anvesh Balabhadra
- Neurology, Hartford Hospital & University of Connecticut, UNITED STATES
| | - Shivam Patel
- Neurology, UConn School of Medicine, UNITED STATES
| | | | - Sheila Co Martins
- Stroke Unit, Neurology Service, Hospital de Clinicas de Porto Alegre, BRAZIL
| | | | - Young Dae Kim
- Department of Neurology, Yonsei University College of Medicine, KOREA, REPUBLIC OF
| | - Balaji Krishnaiah
- Neurology, University of Tennnessee Health Science Center, UNITED STATES
| | | | | | - Abid Y Qureshi
- Department of Neurology, University of Kansas Medical Center, UNITED STATES
| | - Sebastian Fridman
- Department of Clinical Neurological Sciences, University of Western Ontario - London Health Science Centre, CANADA
| | | | - Farid Khasiyev
- Neurology, Saint Louis University School of Medicine, UNITED STATES
| | - Guillermo Linares
- Souers Stroke Institute, Saint Louis University School of Medicine, UNITED STATES
| | | | | | - Sofia Vassilopoulou
- 1st Department of Neurology, Eginition Hospital, National and Kapodistrian University of Athens, GREECE
| | | | | | | | | | - Sleiman El Jamal
- Neurology, Rhode Island Hospital & Alpert Medical School of Brown University, UNITED STATES
| | - Shilin Liu
- University of Science and Technology, CHINA
| | | | | | | | - Rami Z Morsi
- Department of Neurology, University of Chicago, UNITED STATES
| | - Tareq Kass-Hout
- Department of Neurology, University of Chicago, UNITED STATES
| | - Feina Shi
- Department of Neurology, Sir Run Run Shaw Hospital of Zhejiang University, School of Medicine, CHINA
| | - Jinhua Zhang
- Department of Neurology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, CHINA
| | | | | | | | | | - Shayak Sen
- Cedars Sinai Medical Center, UNITED STATES
| | | | - Marwa Elnazeir
- Department of Neurology, University of Louisville, UNITED STATES
| | - Han Xiao
- Economics, University of California Santa Barbara, UNITED STATES
| | | | - Farhan Khan
- Neurology, Alpert Medical School, Brown University, UNITED STATES
| | - Christoph Stretz
- Neurology, Warren Alpert Medical School of Brown University, UNITED STATES
| | | | - Eric D Goldstein
- Neurology, Warren Alpert Medical School of Brown University, UNITED STATES
| | - Karen L Furie
- Department of Neurology, Rhode Island Hospital, UNITED STATES
| |
Collapse
|
2
|
Grottoli S, Bianchi A, Bogazzi F, Bona C, Carlsson MO, Colao A, Dassie F, Giampietro A, Gomez R, Granato S, Maffei P, Pivonello R, Prencipe N, Ragonese M, Urbani C, Cannavò S. Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY. J Endocrinol Invest 2022; 45:1535-1545. [PMID: 35359232 PMCID: PMC9270309 DOI: 10.1007/s40618-022-01789-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Accepted: 03/16/2022] [Indexed: 10/31/2022]
Abstract
OBJECTIVE A comprehensive picture of pegvisomant use for treating acromegaly in routine clinical practice in different countries is lacking. We aimed, therefore, to document country-specific behaviors in real-life pegvisomant use, and the main safety and effectiveness outcomes in the ACROSTUDY. DESIGN ACROSTUDY is an open-label, non-interventional, post-marketing safety surveillance study. METHODS A descriptive analysis was performed using data from the six top-recruiter ACROSTUDY countries, i.e., Germany (n = 548 patients), Italy (n = 466), France (n = 312), USA (n = 207), Spain (n = 200) and the Netherlands (n = 175). These nations accounted for > 85% of the ACROSTUDY cases. RESULTS The mean pegvisomant dose at treatment start was lowest in the Netherlands (9.4 mg/day), whereas it ranged between 10.9 and 12.6 mg/day in the other countries. At year 5, the mean pegvisomant dose was around 15 mg/day in all countries, except France (18.1 mg/day). At starting pegvisomant, patients treated with monotherapy ranged between 15% in the Netherlands and 72% in Spain. Monotherapy remained lowest over time in the Netherlands. In all countries, the percentage of patients with normal IGF-1 increased steeply from < 20% at baseline to 43-58% at month 6 and 51-67% at year 1. After that, we observed minor changes in the rate of acromegaly control in all countries. The Netherlands peaked in disease control at year 2 (72%). The proportion of patients reporting changes in pituitary tumor size was generally low. Serious treatment-related adverse events were < 5% in all countries. CONCLUSIONS Our study provided a detailed summary of real-life use of pegvisomant in the six top-recruiter ACROSTUDY nations.
Collapse
Affiliation(s)
- S Grottoli
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Science, University of Turin, Corso Dogliotti 14, 10126, Turin, Italy.
| | - A Bianchi
- Pituitary Unit, Department of Endocrinology, Fondazione A Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
| | - F Bogazzi
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - C Bona
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Science, University of Turin, Corso Dogliotti 14, 10126, Turin, Italy
| | - M O Carlsson
- Global Medical Affairs, Pfizer Rare Disease, Brussels, Belgium
| | - A Colao
- Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, 80131, Naples, Italy
| | - F Dassie
- Department of Medicine, Padua University Hospital, Padua, Italy
| | - A Giampietro
- Pituitary Unit, Department of Endocrinology, Fondazione A Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
| | - R Gomez
- Global Medical Affairs, Pfizer Rare Disease, Brussels, Belgium
| | - S Granato
- Medical Department, Pfizer Italia, Rome, Italy
| | - P Maffei
- Department of Medicine, Padua University Hospital, Padua, Italy
| | - R Pivonello
- Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, 80131, Naples, Italy
| | - N Prencipe
- Division of Endocrinology, Diabetology and Metabolism, Department of Medical Science, University of Turin, Corso Dogliotti 14, 10126, Turin, Italy
| | - M Ragonese
- Unit of Endocrinology, Department of Human Pathology, University of Messina, Messina, Italy
| | - C Urbani
- Endocrinology II Unit, Department of Medicine, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
| | - S Cannavò
- Unit of Endocrinology, Department of Human Pathology, University of Messina, Messina, Italy
| |
Collapse
|
3
|
Ringer A, Smichowski AM, Gomez R, Virasoro BM, Martinez L, Bertiller E, Siegrist C, Abdala B, Chulibert S, Grossi DG, Rubin E, Kostianovsky A, Munoz SA, Gandino I. POS1334 OCULAR CICATRICIAL PEMPHIGOID: IS THERE AN ASSOCIATION WITH AUTOIMMUNE DISEASES? Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundOcular Cicatricial Pemphigoid (OCP) is an infrequent, systemic cicatricial immune-mediated disease, belonging to the group of membranous-mucosal pemphigoids (MMP). Due to the possibility of coexistence of multiple autoimmune diseases (ADs), OCP could be associated with other diseases. In the literature, association of OCP and ADs is reported in 9-35% of patients, but most reports correspond to MMP.ObjectivesTo assess the prevalence of autoimmune diseases associated with OCP and to analyse clinical, laboratorial and treatment associations between these entities.MethodsA multicentre cross-sectional study of patients with a diagnosis (clinical and/or by biopsy) of OCP derived from ophthalmology was performed.The population was divided into two groups according to their association or not with other ADs. Clinical, laboratorial and treatment variables were described and compared between both groups. In addition, a multivariate descriptive logistic regression analysis was performed to identify variables that could suggest the association between OCP and ADs.ResultsA total of 88 patients were recruited, 66 (75%) females, with a mean age at diagnosis of 64.3 years (SD 11.9). The median follow-up time was 1 year. The diagnosis was done by biopsy in 86,8%. Ocular bilateral disease was present in 95,3% of patients. There was a median delay from symptoms onset to diagnosis of 2 years. A history of malignancy was reported in 13,6%. Extraocular involvement was evidenced in 11,5% (4% compromised skin and 9,1% other mucous membranes). Regarding the previous clinical findings, no statistically significance was found between the groups with and without ADs. Systemic treatment was depicted as follows: oral corticosteroids (60,2%) (p-value < 0.001), corticosteroids pulses (5,7%), dapsone (3,4%), methotrexate (79,5%), mycophenolate (15,9%), azathioprine (23,9%), rituximab (5,7%), immunoglobulin (1,1%); topical corticosteroids (96,6%) and ocular infiltration (2,3%). The group associated ADs included 24 patients (27.3%). Within them, the most prevalent diagnosis was Sjogren’s syndrome (13.6%), followed by Hashimoto´s thyroiditis (9,1%) and rheumatoid arthritis (3,4%). Most of the patients presented Foster stages 1 (45.3%) and 2 (29.3%) at diagnosis. In the ADs group, statistically significant associations were observed with ANA, SS-A and SS-B antibodies, rheumatoid factor, and hypergammaglobulinemia. In the descriptive multivariate logistic regression model, it was detected that hypergammaglobulinemia was associated with ADs and OCP, adjusted for age, sex, smoking, skin and mucosal involvement, and erythrocyte sedimentation rate (OR 8.7; 95% CI 1.6 to 46.8; p= 0.012), Table 1.Table 1.Multiple logistic regression analysis with OCP associated with ADs as dependent variable.ORCI95P valueGender0.20.04 - 1.10.07Age at diagnosis1.020.9 - 1.10.25Smoking0.50.1 - 1.70.26Skin and mucosa compromise1.20.2 - 8.20.83ESR0.980.95 - 1.020.58Hypergammaglobulinemia8.71.6 - 46.80.012ESR: Erythrocyte Sedimentation Rate. OR: Odd Ratio. CI95: confidence intervalConclusionDue to the autoimmune nature of OCP, it could coexist with other ADs. In this research, it was observed that more than a quarter of the population presented with such association and hypergammaglobulinemia could suggest it. A systematic search for this coexistence should be carried out to avoid sequelae or incomplete treatment in pathologies that are currently potentially treatable.References[1]Lamberts A et al. European guidelines on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I. 2021;1750–64.[2]Schmidt E et al. European Guidelines on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II. 2021;1926–48.[3]Narla S, Silverberg JI. Associations of pemphigus or pemphigoid with autoimmune disorders in US adult inpatients. J Am Acad Dermato. 2019;15-25.AcknowledgementsOn behalf of the Study Working Group of Rheumatological Ocular Diseases, Argentinian Society of Rheumatology.Disclosure of InterestsNone declared
Collapse
|
4
|
Holguín Arias LL, Sorrentino L, Brigante A, Yucra D, Hamaui A, Rivero M, Menendez MS, Soliz C, Menendez MDLP, Gomez R, Iudici M, Benitez A, Gamba J, Peon C, Dubinsky D. AB0736 ASSOCIATION BETWEEN ERYTHROCYTE DISTRIBUTION WIDTH AND SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundInterstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) account for 60% of deaths related to scleroderma (SSc). The erythrocyte distribution width (RDW) has been used as a marker of poor prognosis in different pathologies. In SSc, RDW has been found to be elevated in PAH and has been proposed as a predictor of cardiorespiratory compromise.ObjectivesThe aim of this study is to evaluate the association between increased RDW and the presence of EPI in patients with SSc.MethodsThis is a multicenter, retrospective, cross-sectional study of patients diagnosed with SSc (ACR/EULAR 2013) from January 2011 to August 2021. Other concomitant autoimmune diseases, malignancy, active infections, iron-deficiency or pernicious anaemia and transfused patients were excluded. The diagnosis of PID was made by high-resolution computed tomography (HR-CT) and the extension evaluated by Goh criteria. A review of medical records was conducted, collecting clinical and demographic characteristics, interstitial pattern by HR-CT, assessed, acute phase reactants, capillaroscopy, functional respiratory tests (PFT) and echocardiographic resolution. Patients diagnosed with PAH by right heart catheterization were not excluded in this study but recorded.ResultsSeventy-five patients were included, with a mean age of 59.4 (SD 14.1 CI95% 56-6), from which 67 (89%) were women. A median of 8 years of disease evolution was observed RIC 8). Limited SS was observed in 50 (66%) and diffuse SS in 24 (32%). EPI was observed in 50 (66%) of which NSIP 25 (33%), NSIP-f 15 (20%) and UIP 10 (13%). The extension of the disease was limited in 25 (33%) and extensive in 19 (25%). Capillaroscopic findings were normal in 2 (3.4%), nonspecific in 1 (1.7%), early SD in 9 (15.3%), active SD in 22 (37.3%), and late SD in 25 (42.4%); in sixteen patients there was no capillaroscopy.We observed an increase in RDW in the EPI group with a statistically significant difference OR 6.06 CI95% 2-17 (p 0.001).The median RDW is higher in patients with ILD and PAH than in healthy people (p<0.0001).We found a low negative correlation between RDW / FVC r (63) -.25 p 0.042 and RDW / FEV1 r (63) .30 p 0.015.ConclusionIn the present study we have been able to evidence that there is a statistically significant relationship between the percentage of RDW and the presence of PID. When analysing the association between patients without pulmonary compromise, ILD and PAH and the percentage of RDW, we were able to find a statistically significant difference between the three groups. It is necessary to continue with studies with a larger number of patients to grant robustness to the results.References[1]Muangchan, et al: 15% rule in SSc. The Journal of Rheumatology 2013; 40; 9; doi:10.3899/jrheum.121380.[2]Cottin and Brown. Interstitial lung disease associated with systemic sclerosis (Ssc-ILD) Respiratory Research (2019) 20:13[3]Thayer, T. E. et al. Unbiased Phenome-wide Association Studies of Red Cell Distribution Width Identifies Key Associations with Pulmonary Hypertension. Annals of the American Thoracic Society. doi:10.1513/annalsats.201809-594oc.[4]Zhao J,Mo H, Guo X,Wang Q, Xu D, Hou Y, Tian Z, Liu Y,Wang H, Lai J, Li M, ZengX (2018) Red blood cell distribution width as a related factor of pulmonary arterial hypertension in patients with systemic sclerosis. Clin Rheumatol 37:979–985.[5]Goh NSL, Desai SR, Veeraraghavan S, et al. Interstitial Lung Disease in Systemic Sclerosis: A Simple Staging System. American Journal of Respiratory and Critical Care Medicine. 2008. June;177(11):1248–54.[6]Hax V, Bredemeier M, Didonet Moro AL, et al. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis. Seminars in Arthritis and Rheumatism. 2017. October;47(2):228–34.[7]Peralta S. Guías Argentinas De Consenso En Diagnóstico Y Tratamiento De La Hipertensión Pulmonar. Sociedad Argentina de Cardiología. Área de Consensos y Normas. Vol 85 Suplemento 3. Octubre 2017.AcknowledgementsParticipating centersDisclosure of InterestsNone declared
Collapse
|
5
|
Henderson K, Ibragimov A, Gomez R, Chakraborty S, Chakraborty T. Does estrogen show neuroprotective effects on hypothalamic cells when induced by beta amyloid? FASEB J 2022. [DOI: 10.1096/fasebj.2022.36.s1.0r742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | | | - Roberto Gomez
- Department of BiologyAdelphi UniversityGarden CityNY
| | - Sanjoy Chakraborty
- Department of Biological SciencesNew York City College of TechnologyNew YorkNY
| | | |
Collapse
|
6
|
Knauer N, Pashkina E, Kozlov V, Gomez R, Caminade AM, Kahlert U, Apartsin E. 49P Antitumor effects of cationic dendritic molecules and their complexes with microRNA in glioblastoma stem-like cells. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.01.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
7
|
Guzman I, Gomez R. Advantages of using the optic nerve ecography to predict clinical progression in multiple sclerosis. Neurología (English Edition) 2022; 37:73. [DOI: 10.1016/j.nrleng.2021.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2021] [Accepted: 07/07/2021] [Indexed: 10/19/2022] Open
|
8
|
Guzman I, Gomez R. Advantages of using the optic nerve ecography to predict clinical progression in multiple sclerosis. Neurologia 2022; 37:73. [PMID: 34531046 DOI: 10.1016/j.nrl.2021.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2021] [Revised: 07/06/2021] [Accepted: 07/07/2021] [Indexed: 11/19/2022] Open
Affiliation(s)
- I Guzman
- Professional School of Human Medicine, San Juan Bautista Private University, Av. Antonio Lavalle S/N, Chorrillos, Lima 15067, Perú.
| | - R Gomez
- Professional School of Human Medicine, San Juan Bautista Private University, Av. Antonio Lavalle S/N, Chorrillos, Lima 15067, Perú
| |
Collapse
|
9
|
Gomez R, Hafezi N, Amrani M, Schweiger S, Dewenter MK, Thomas P, Lieb C, Hasenburg A, Skala C. Genetic findings in miscarriages and their relation to the number of previous miscarriages. Arch Gynecol Obstet 2021; 303:1425-1432. [PMID: 33211176 PMCID: PMC8087554 DOI: 10.1007/s00404-020-05859-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2020] [Accepted: 10/26/2020] [Indexed: 11/28/2022]
Abstract
PURPOSE Early pregnancy loss leads to a devastating situation for many couples. Genetic disorders found in the pregnancy tissue are a frequent cause of miscarriages. It is unclear whether maternal age or previous miscarriages are associated with a higher chromosomal anomaly rate. This study aimed to determine the cytogenetical distribution of chromosomal disorders in couples after one or more previous miscarriages as well as the influence of maternal age. METHODS 406 fetal tissue samples obtained after spontaneous abortion between 2010 and 2014 were successfully karyotyped. This included 132 couples with at least two losses and 274 couples with sporadic miscarriage. Normal and abnormal karyotype rate was determined for age, parity, gravidity, gestational week and number of previous miscarriages by logistic regression analysis. RESULTS 145 (35.71%) fetal tissue samples had a normal karyotype, and 261 (64.8%) did not. After adjusting for age, older patients have a statistically significantly higher probability of genetic disorders in the pregnancy tissue (p < 0.001, OR 1.064, 95% CI 1.03-1.11). With each additional year, the probability of finding chromosomal abnormalities in a miscarriage increased by 6.4%. Patients younger than 35 years have a lower probability of having chromosomal disorders in the aborted material after two or more miscarriages than after sporadic miscarriages (50.7 vs. 58.9%) (p = 0.014, OR 0.67, 95% CI 0.48-0.914). Nevertheless, the risk of embryonic chromosomal disorders in patients aged 35 and above increased from 75.5% in sporadic miscarriages to 82.4% after more than one pregnancy losses (p = 0.59, OR 1.14, 95% CI - 0.72 to 1.92). CONCLUSION Chromosomal disorders found after one or more previous miscarriages are related to patients' age. Couples suffering two or more miscarriages should be further researched, especially in younger patients.
Collapse
Affiliation(s)
- R Gomez
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz, Germany.
- Kinderwunschzentrum der Universitätsmedizin der Johannes Gutenberg Universität Mainz, Langenbeckstr. 1, 55131, Mainz, Germany.
| | - N Hafezi
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz, Germany
| | - M Amrani
- Vivaneo Kinderwunschzentrum Wiesbaden, Wiesbaden, Germany
| | - S Schweiger
- Institut für Humangenetik, Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz, Germany
| | - M K Dewenter
- Institut für Humangenetik, Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz, Germany
| | - P Thomas
- Institut für Humangenetik, Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz, Germany
| | - C Lieb
- IMBEI Institut für medizinische Epidemiologie, Johannes Gutenberg Universität Mainz, Mainz, Germany
| | - A Hasenburg
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz, Germany
| | - C Skala
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin der Johannes Gutenberg Universität Mainz, Mainz, Germany
- Kinderwunschzentrum der Universitätsmedizin der Johannes Gutenberg Universität Mainz, Langenbeckstr. 1, 55131, Mainz, Germany
| |
Collapse
|
10
|
Maliandi MDR, Malvano YS, Cusa A, Gamba MJ, Gomez R, Got J, Gut O, Paris UV, Spinetto MA, Mariach C, Abalo AI, Estevez A, Velazco Zamora JL, Vinicki JP. POS0667 TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN REAL-WORLD SETTINGS: A NATIONAL MULTICENTER STUDY OF 167 PATIENTS FROM ARGENTINA. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Tofacitinib (TOF), an oral JAK inhibitor, is approved for the treatment of rheumatoid arthritis (RA) either as monotherapy or in combination with background methotrexate (MTX). Despite the current evidence of efficacy from randomized controlled trials and open-label long-term extension studies, evidence of effectiveness and safety in real-world settings is limited, not only in Argentina but also in Latin America.Objectives:To describe effectiveness, safety and persistence of TOF therapy in RA patients from public and private medical centers from Argentina. In addition, establish prognostic factors for clinical remission at 3 months and TOF monotherapy at 12 months.Methods:A retrospective, observational and multicentre study was performed from an analysis of medical records of 10 medical centers. RA patients (ACR/EULAR, 2010) and age ≥ 18 years who had received or are under treatment with TOF until June 2020 were included. The data collection was done on a standard database that included baseline data and at 3, 6 and 12 months. Clinical remission was defined as DAS28-ESR < 2,6. Adverse events, treatment duration, TOF treatment persistence at last visit and discontinuation cause were assessed. Comparison to baseline values was performed using Wilcoxon sign for numerical variables and McNemar´s test for categorical variables. Treatment persistence was analyzed using Kaplan Meier´s technique. Multivariate analysis was performed using R software and its library packages (Lme4, Tidyverse and ggpubr). A p value < 0.05 was considered significant.Results:A total of 167 patients were included (78.4% were female). At baseline, the median age was 53 years (IQR 43-63 years), median disease duration was 4 years (IQR 2-13 years). RF was positive in 85.6% of patients, ACPA in 80.8% and structural radiological damage was present in 71.8%. Previous use of MTX was 97%, leflunomide 74.8% and biologic therapy 42.5% (28.74% 1 biologic, 11.98% 2 biologics and 1.8% ≥ 3 biologics). TOF dose: 48% 11 mg/day and 52% 5 mg BID. A statistically significant difference was observed not only in disease activity (p<0.0001) but also in the requirement of MTX and PDN (p<0.0001) in the 12 months evaluated. Remission significantly increased from baseline to month 3 and to a much lesser extent to month 6 (p < 0.001). The mean duration of treatment with TOF was 20.10 ± 15.25 months. Treatment persistence was 93.84% at 3 months and 91.24% at 6 months. In those patient who achieved REM at month 3, a statistically significant differences in duration of RA (p 0.0002), structural radiological damage (p 0.011), basal disease activity (p 0.018) and prior treatment with biological therapy (p 0.017) was found when compared with patients who remained active. Furthermore, in univariate logistic regression analysis, 5 years or more of disease duration was associated with a 3 times higher risk of not achieving clinical remission at 3 months (odds ratio = 0.35, 95% CI = 0.15-0.83). In the multivariate logistic regression analysis, previous biological therapy was the only predictor associated with a decrease in the probability of clinical remission (p < 0.008). Adverse events were registered in 26 patients (herpes zoster, n = 9).Conclusion:The effectiveness of TOF was observed not only in the clinical response achieved but also in the dose titration or withdrawal of MTX and PDN. The safety profile did not show any difference from long-term extension studies. At 12 months, 86.81% of the patients persisted with TOF therapy. We found prognostic factors associated with clinical remission at 3 months but those associated with monotherapy at 12 months could not be defined due to small number of patients analyzed that could have generated lack of statistical power, although more studies are required to confirm these assumptions.Disclosure of Interests:Maria Del Rosario Maliandi: None declared, Yanina Silvia Malvano: None declared, Alejandra Cusa: None declared, María Julieta Gamba: None declared, Ramiro Gomez Speakers bureau: Abbvie, Novartis, Julio Got: None declared, Oscar Gut: None declared, Ursula Vanesa Paris: None declared, Maria Andrea Spinetto: None declared, Carolina Mariach: None declared, Alejandra Ines Abalo: None declared, Adrián Estevez Speakers bureau: Bristol-Meyer-Squibb, Jose Luis Velazco Zamora: None declared, Juan Pablo Vinicki: None declared
Collapse
|
11
|
Benegas M, Orozco C, Giorgis P, Schneeberger EE, Bande JM, Medina MA, Iraheta I, Airoldi C, Girard Bosch P, Scarafia S, Velozo E, Rillo O, Guinsburg M, Cowan MP, Piovesan M, Martire V, Casalla L, Cosentino V, Gonzalez P, Peon C, Gomez R, Benitez A, Gamba MJ. POS1005 ASSESSMENT OF DAREA AND MODIFIED DAREA IN AN ARGENTINIAN-GUATEMALAN REACTIVE ARTHRITIS COHORT. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Reactive Arthritis (ReA) is an inflammatory joint disease and, as in rheumatoid or psoriatic arthritis, composite indices are the most useful tools to measure disease activity. The Disease Activity Index for Reactive Arthritis (DAREA) is the only developed index for ReA, which requires a 66/68 joint count and CRP for its assessment, the latter being difficult to acquire in our setting. Therefore, we developed a simplified index, the modified DAREA (DAREAm), with a lower joint count and ESR for its evaluation.Objectives:1) To evaluate the DAREA and the DAREAm in a cohort of patients with diagnosis of ReA and post-infectious arthritis 2) To assess the correlation of the DAREA and DAREAm with several clinical variables, functional capacity and quality of life in a cohort of patients with ReA.Methods:Patients with diagnosis of ReA (Calin’79) and post-infectious arthritis were included. Demographic data were collected, patient´s pain and global assessment were evaluated through a visual analog scale (VAS) and a 3-point scale (no pain = 0, mild = 1, moderate = 2, severe = 3), physician´s global assessment, morning stiffness (MS) and VAS fatigue. Functional capacity was assessed by HAQ and quality of life according to EuroQol-5 dimensions (EQ-5D), and the activity indices DAS28, DAREA and DAREAm were calculated. Statistical analysis: a descriptive analysis of the variables and correlation between numerical variables with Spearman rank correlation were performed.Results:57 patients were included, 53 with diagnosis of ReA, the majority post urogenital (63%) and gastrointestinal (17%), and 4 with diagnosis of post-infectious arthritis. Fifty six percent were male, mean age: 40 years old (SD ± 14) and median ReA duration: 15 months (IQR 2-45). The number of painful and swollen joints in a 66/68 joint count showed a median of 2 (IQR 0-3) and 1 (IQR 1-2) respectively. Median VAS pain 43 (IQR 15-70), patient´s disease activity 40 (IQR 20-60) and physician´s 40 (IQR 20-60), MS 10 (IQR 0-50) and fatigue 30 (IQR 0-80). Median DAS28 3.6 (IQR 2.3-4.3), DAREA 7.4 (IQR 2.5-10.6), DAREAm 8.6 (IQR 4.6-12.7), HAQ 0.625 (IQR 0.125-1). The dimensions with the greatest compromise in the EQ-5D were pain/discomfort (63%) and anxiety/depression (51%), and the median VAS EQ-5D was 60 (IQR 32-80). DAREA correlated with DAREAm (rs= 0.89; p <0.001), DAS28 (rs= 0.84; p <0.001), medical VAS (rs= 0.60; p <0.001), MS (rs= 0, 50; p <0.001), HAQ (rs= 0.53; p <0.001), VAS fatigue (rs= 0.57; p <0.001) and mobility subscales of the EQ5D (rs= 0.56; p <0.001), pain/discomfort (rs= 0.49; p <0.001) and anxiety/depression (rs= 0.61; p <0.001). The DAREAm correlated with DAS28 (rs= 0.93; p <0.001), physician VAS (rs= 0.58; p <0.001), fatigue VAS (rs= 0.53; p <0.001), HAQ (rs= 0 .51; p <0.001) and the EQ5D subscales: mobility (rs= 0.64; p <0.001), pain/discomfort (rs= 0.56; p <0.001) and anxiety/depression (rs= 0.66; p <0.001)Conclusion:This is the first study that assess activity indices in a cohort of patients with ReA. The DAREAm demonstrated a very good correlation with both DAREA and DAS28. We encourage the use of this simplified index in daily practice to evaluate patients with ReA.Disclosure of Interests:None declared.
Collapse
|
12
|
Vera-Puerto I, Valdés H, Correa C, Perez V, Gomez R, Alarcon E, Arias C. Evaluation of Bed Depth Reduction, Media Change, and Partial Saturation as Combined Strategies to Modify in Vertical Treatment Wetlands. Int J Environ Res Public Health 2021; 18:4842. [PMID: 34062738 PMCID: PMC8124162 DOI: 10.3390/ijerph18094842] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Revised: 04/28/2021] [Accepted: 04/29/2021] [Indexed: 11/18/2022]
Abstract
The aim of this work was to evaluate the performance of vertical subsurface flow treatment wetlands (VSSF TWs) for treating rural domestic wastewater when strategies such as bed depth reduction and media change are used in combination with bottom saturation. Two treatment wetland systems were implemented: normal (VF-N), with a bed depth of 1.0 m, and modified (VF-M), with a bed depth of 0.5 m and a bottom layer of natural zeolite. Schoenoplectus californicus was used as experimental plant. These two treatment systems were operated at a hydraulic loading rate of 120 mm/d in two phases. Phase I did not use bottom saturation, while Phase II involved a bottom saturation of the zeolite layer of the VF-M system. The results show that bed depth reduction did not have a significant effect (p > 0.05) in terms of organic matter, solids, and ammonium removal. Conversely, it had a significant influence (p < 0.05) on phosphate as well as a negative effect on pathogen removal. This influence could be explained by initial media capacity for phosphorus removal and filtration importance in the case of pathogens. Partial saturation only had a positive influence on total nitrogen removal. The addition of a bottom layer of natural zeolite showed no positive effect on nutrient removal. The plant showed adaptation and positive development in both VF-N and VF-M. The water balance showed that water loss was not influenced by bed depth reduction. Therefore, according to the previous results, a combination of the proposal modifications to VSSF TWs can be introduced for treating rural domestic wastewater.
Collapse
Affiliation(s)
- Ismael Vera-Puerto
- Centro de Innovación en Ingeniería Aplicada, Departamento de Obras Civiles, Facultad de Ciencias de la Ingeniería, Universidad Católica del Maule, Av. San Miguel 3605, Talca 3480112, Chile; (I.V.-P.); (C.C.); (E.A.)
| | - Hugo Valdés
- Centro de Innovación en Ingeniería Aplicada, Departamento de Computación e Industrias, Facultad de Ciencias de la Ingeniería, Universidad Católica del Maule, Av. San Miguel 3605, Talca 3480112, Chile;
| | - Christian Correa
- Centro de Innovación en Ingeniería Aplicada, Departamento de Obras Civiles, Facultad de Ciencias de la Ingeniería, Universidad Católica del Maule, Av. San Miguel 3605, Talca 3480112, Chile; (I.V.-P.); (C.C.); (E.A.)
| | - Valeria Perez
- Escuela de Ingeniería en Construcción, Departamento de Obras Civiles, Facultad de Ciencias de la Ingeniería, Universidad Católica del Maule, Av. San Miguel 3605, Talca 3480112, Chile; (V.P.); (R.G.)
| | - Roberto Gomez
- Escuela de Ingeniería en Construcción, Departamento de Obras Civiles, Facultad de Ciencias de la Ingeniería, Universidad Católica del Maule, Av. San Miguel 3605, Talca 3480112, Chile; (V.P.); (R.G.)
| | - Erica Alarcon
- Centro de Innovación en Ingeniería Aplicada, Departamento de Obras Civiles, Facultad de Ciencias de la Ingeniería, Universidad Católica del Maule, Av. San Miguel 3605, Talca 3480112, Chile; (I.V.-P.); (C.C.); (E.A.)
| | - Carlos Arias
- Department of Biology-Aquatic Biology, Aarhus University, Ole Worms Allé 1, 8000 Aarhus C, Denmark
- WATEC Aarhus University Centre for Water Technology, NyMunkegade, Bldg. 1521, 8000 Aarhus C, Denmark
| |
Collapse
|
13
|
COX J, Boily M, Caron A, Chong O, Ding J, Dumais V, Gaudreault S, Gomez R, Guthrie J, King A, Oballa R, Sheng T, Surendradoss J, Wu J, Powell D. POS-442 DISCOVERY OF CHK-336: A FIRST-IN-CLASS, LIVER-TARGETED, SMALL MOLECULE INHIBITOR OF LACTATE DEHYDROGENASE FOR THE TREATMENT OF PRIMARY HYPEROXALURIA. Kidney Int Rep 2021. [DOI: 10.1016/j.ekir.2021.03.467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
14
|
Jesser E, Yeguerman C, Stefanazzi N, Gomez R, Murray AP, Ferrero AA, Werdin-González JO. Ecofriendly Approach for the Control of a Common Insect Pest in the Food Industry, Combining Polymeric Nanoparticles and Post-application Temperatures. J Agric Food Chem 2020; 68:5951-5958. [PMID: 32356980 DOI: 10.1021/acs.jafc.9b06604] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
One of the most common insect pests is Plodia interpunctella (Hübner) (Lepidoptera: Pyralidae), which affects different food commodities. A new effective approach for the management of insect pests is the development of new formulations based on essential oils (EO). However, few works informed about the relationship between insecticidal activity of EO or essential oils loaded polymeric nanoparticles (EOPN) and post-application temperature. In our work, palmarosa [Cymbopogon martinii (Roxb.) Watson], geranium (Geranium maculatum L.), and peppermint (Mentha piperita L.) oils were formulated in a polyethylene glycol 6000 matrix to obtain EOPN. Geranium and palmarosa EOPN had sizes of 259 and 191 nm, respectively; the encapsulation efficiency (EE) was close to 90%, and the samples were monodisperse. The sizes from peppermint EOPN were around 380 nm, with an EE of 72%, and were polidisperse. In a contact toxicity bioassay, the insecticidal effect of the oils was increased by all EOPN, with palmarosa oil being the most toxic. In addition, the oils and their nanoparticles showed a significantly negative temperature coefficient when applied by contact. In a fumigant bioassay, just palmarosa and peppermint EOPN enhanced the oil activity and palmarosa EO and EOPN showed the highest toxic effect. In this case, the EO and EOPN insecticidal activity was unaffected by environmental temperature variation.
Collapse
Affiliation(s)
- E Jesser
- Instituto de Ciencias Biológicas y Biomédicas del Sur (INBIOSUR), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional del Sur, San Juan 670, Bahía Blanca, Buenos Aires B8000CPB, Argentina
- Laboratorio de Zoología de Invertebrados II, Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur, San Juan 670, Bahía Blanca, Buenos Aires B8000CPB, Argentina
| | - C Yeguerman
- Laboratorio de Zoología de Invertebrados II, Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur, San Juan 670, Bahía Blanca, Buenos Aires B8000CPB, Argentina
| | - N Stefanazzi
- Instituto de Ciencias Biológicas y Biomédicas del Sur (INBIOSUR), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional del Sur, San Juan 670, Bahía Blanca, Buenos Aires B8000CPB, Argentina
- Laboratorio de Zoología de Invertebrados II, Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur, San Juan 670, Bahía Blanca, Buenos Aires B8000CPB, Argentina
| | - R Gomez
- Laboratorio de Zoología de Invertebrados II, Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur, San Juan 670, Bahía Blanca, Buenos Aires B8000CPB, Argentina
| | - A P Murray
- Instituto de Química del Sur (INQUISUR), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional del Sur, Avenida Alem 1253, Bahía Blanca, Buenos Aires B8000CPB, Argentina
| | - A A Ferrero
- Instituto de Ciencias Biológicas y Biomédicas del Sur (INBIOSUR), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional del Sur, San Juan 670, Bahía Blanca, Buenos Aires B8000CPB, Argentina
- Laboratorio de Zoología de Invertebrados II, Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur, San Juan 670, Bahía Blanca, Buenos Aires B8000CPB, Argentina
| | - J O Werdin-González
- Laboratorio de Zoología de Invertebrados II, Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur, San Juan 670, Bahía Blanca, Buenos Aires B8000CPB, Argentina
- Instituto de Química del Sur (INQUISUR), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional del Sur, Avenida Alem 1253, Bahía Blanca, Buenos Aires B8000CPB, Argentina
| |
Collapse
|
15
|
Gomez R, Sussman A, Kano M, Boyce T, Chen L, Gundelach A, Dayao Z, Pestak C, Rutledge T. Developing a Survivorship Care Transition Model for Rural and Underserved Low Risk Breast and Gynecologic Cancer Patients. Gynecol Oncol 2020. [DOI: 10.1016/j.ygyno.2019.11.121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Velandia-Martínez A, Ortega-Sanchez MA, Martínez-Perez SO, Peña I, Pradilla O, Gomez R, Martínez-Perez A. Parry-Romberg Syndrome and Temporal Lobe Refractory Epilepsy: Case Report. J Epilepsy Res 2019; 9:157-160. [PMID: 32509553 PMCID: PMC7251345 DOI: 10.14581/jer.19020] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2018] [Revised: 01/13/2020] [Accepted: 01/24/2020] [Indexed: 11/05/2022] Open
Abstract
The Parry-Romberg syndrome (PRS), also known as hemifacial atrophy, is a rare neurocutaneous disease with the prevalence of 1/700,000 cases. It is more common in women than men, with an early onset of disease usually within the first two decades of life. Even though the etiology of PRS is unknown, it is thought to be a multifactorial disease that involves hereditary, posttraumatic, autoimmune, infectious, and neoplastic factors. There are a variety of systemic manifestations described in PRS including neurological conditions that range from intractable headache to refractory epilepsy. The manifestations must be identified in a timely manner to ensure an early therapeutic intervention, considering that an appropriate approach during the initial phase might halt the disease progression and markedly improve the quality of life in these patients. This article is aimed to describe the case of a 23 years old female with left hemifacial atrophy and dermatologic, dental, and neurologic compromise, associated with refractory temporal lobe epilepsy evidenced in neuroimaging and electrodiagnostic testings.
Collapse
Affiliation(s)
- A Velandia-Martínez
- Department of Neurology, Carlos Ardila Lulle Medical Center, Santander, Colombia
| | - M A Ortega-Sanchez
- Department of Neurology, Carlos Ardila Lulle Medical Center, Santander, Colombia
| | - S O Martínez-Perez
- Department of Dermatology, Carlos Ardila Lulle Medical Center, Santander, Colombia
| | - I Peña
- Department of Neurology, Carlos Ardila Lulle Medical Center, Santander, Colombia
| | - O Pradilla
- Department of Neurosurgery, Carlos Ardila Lulle Medical Center, Santander, Colombia
| | - R Gomez
- Department of Neurosurgery, Carlos Ardila Lulle Medical Center, Santander, Colombia
| | - A Martínez-Perez
- Department of Neurosurgery, Carlos Ardila Lulle Medical Center, Santander, Colombia.,Department of Radiology, Carlos Ardila Lulle Medical Center, Santander, Colombia
| |
Collapse
|
17
|
Nuñez M, Folgar A, Diez L, Gomez R, Mur E, Sole J. P2.17-31 Central Lung Tumors Treated with Stereotactic Radiotherapy. Toxicity and Early Results in a Single Institution. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Spies-Upton S, Gade S, Gonzalez J, Choi E, Becker C, Creekpaum M, Lucas E, Escher C, Gomez R. A-23 Mental Illness and Emotional Functioning as Moderated by Executive Functioning: Incarcerated Population. Arch Clin Neuropsychol 2019. [DOI: 10.1093/arclin/acz034.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Objective
The purpose of this study is to investigate whether executive functioning will moderate the relationship of a history of mental illness on aggression in a male forensic population.
Method
Using an archival database from a larger study, 232 male inmates (ages 21 and 49 years old) from three medium/maximum Maryland Correctional facilities were recruited using a pseudo-random selection process during intake. Participants were administered three EF tasks (Cambridge Decision Making Task, Logan Stop-Signal Task, and Stroop Interference Task), history of mental illness was obtained using the Symptom Checklist-90, and aggression was assessed with the Novaco Reaction to Provocation Questionnaire.
Results
Hierarchical multiple regressions were conducted. For overall aggression reactivity, inhibition moderated depression (IR2 = .025, F(3, 224) = 9.977, p < .001, β = -.246, p = .015) and psychoticism (IR2 = .019, F(3, 224) = 8.216, p < .001, β = -.136, p = .031). For reactive aggression subtype, inhibition moderated depression (IR2 = .025, F(3, 224) = 2.679, p = .048, β = .071, p = .017). For proactive aggression subtype, cognitive flexibility moderated anxiety (IR2 = .018, F(3, 224) = 4.731, p = .003, β = -.014, p = .039); and depression (IR2 = .022, F(3, 224) = 3.888, p = .010, β = -.017, p = .025).
Conclusions
Overall, there was mixed findings for inhibition. On Cambridge Decision Making task, inhibition moderated the predictive relationship of depression on reactive aggression and psychoticism and overall aggression but not for other measures of inhibition. For another inhibition task (Stroop), inhibition did not significantly moderate any mental illness on severity of aggression. Cognitive flexibility moderated the predictive relationships of anxiety and depression on proactive aggression. Findings suggest targeting cognitive flexibility for inmates diagnosed with anxiety depression, and psychosis when treating aggression in a male forensic population.
Collapse
|
19
|
Calvo AG, Gomez R, Lopez A, Sanchez S, Villarejo P, Padilla D, Manzanedo I, Pereira F, Perez-Viejo E, Gonzalez L, Lopez-Tomassetti E, Hernandez J, Diaz E, Fabra I, Titos A, Pitarch M, Ochando F, Lacueva F. Morbimortality of patients undergoing cytoreduction + closed hipec with co2 agitation system: a multicentre study. Eur J Surg Oncol 2019. [DOI: 10.1016/j.ejso.2018.10.493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
20
|
Calvo AG, Gomez R, Lasa I, Sanchez S, Padilla D, Villarejo P, Manzanedo I, Pereira F, Perez-Viejo E, Gonzalez L, Lopez-Tomassetti E, Hernandez J, Fabra I, Diaz E, Titos A, Pitarch M, Marcello M, Lacueva F. Analysis of the survival of patients undergoing cytoreduction + closed hipec with co2 agitation system: multicenter study. Eur J Surg Oncol 2019. [DOI: 10.1016/j.ejso.2018.10.494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
21
|
Cicali EJ, Blake K, Gong Y, Mougey EB, Al-Atrash H, Chambers N, Denham J, Evans J, George DE, Gomez R, Palomo P, Taufiq S, Johnson JA, Lima JJ, Franciosi JP. Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial. Clin Transl Sci 2018; 12:172-179. [PMID: 30341969 PMCID: PMC6440564 DOI: 10.1111/cts.12589] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2018] [Accepted: 08/28/2018] [Indexed: 12/13/2022] Open
Abstract
The efficacy of proton pump inhibitor (PPI) medications is highly dependent on plasma concentrations, which varies considerably due to cytochrome P450 (CYP2C19) genetic variation. We conducted a pragmatic, pilot study of CYP2C19 genotype‐guided pediatric dosing of PPI medications. Children aged 5–17 years old with gastric‐acid‐related conditions were randomized to receive either conventional dosing of a PPI or genotype‐guided dosing for a total of 12 weeks. Sixty children (30 in each arm) were enrolled and had comparable baseline characteristics. The mean daily omeprazole equivalent dose prescribed to participants across metabolizer phenotype groups was significantly different in the genotype‐guided dosing arm (P < 0.001), but not in the conventional dosing arm. Prescribers waited for the genotype result before prescribing the PPI medication for 90% of the participants in the genotype‐guided dosing arm. The number of participants who reported an infection was marginally lower in genotype‐guided dosing vs. conventional dosing (20% vs. 44%; P = 0.07). Sinonasal symptoms were higher in the conventional dosing arm as compared with genotype‐guided dosing arm: (2.6 (2.0, 3.4) vs. 1.8 (1.0, 2.3), P = 0.031). CYP2C19 genotype‐guided PPI therapy is feasible in a clinical pediatric setting, well accepted by providers, resulted in differential PPI dosing, and may reduce PPI‐associated infections. A future large scale randomized clinical trial of CYP2C19 genotype‐guided pediatric dosing of PPI medications in children is warranted.
Collapse
Affiliation(s)
| | - Kathryn Blake
- Nemours Children's Specialty Care, Jacksonville, Florida, USA
| | - Yan Gong
- University of Florida, Gainesville, Florida, USA
| | - Edward B Mougey
- Nemours Children's Specialty Care, Jacksonville, Florida, USA
| | - Hadeel Al-Atrash
- Nemours Children's Hospital, Orlando, Florida, USA.,University of Central Florida College of Medicine, Orlando, Florida, USA
| | | | - Jolanda Denham
- Nemours Children's Hospital, Orlando, Florida, USA.,University of Central Florida College of Medicine, Orlando, Florida, USA
| | - Jonathan Evans
- Nemours Children's Specialty Care, Jacksonville, Florida, USA
| | - Donald E George
- Nemours Children's Specialty Care, Jacksonville, Florida, USA
| | - Roberto Gomez
- Nemours Children's Hospital, Orlando, Florida, USA.,University of Central Florida College of Medicine, Orlando, Florida, USA
| | - Pablo Palomo
- Nemours Children's Hospital, Orlando, Florida, USA.,University of Central Florida College of Medicine, Orlando, Florida, USA
| | - Salik Taufiq
- Nemours Children's Specialty Care, Jacksonville, Florida, USA
| | | | - John J Lima
- Nemours Children's Specialty Care, Jacksonville, Florida, USA
| | - James P Franciosi
- Nemours Children's Hospital, Orlando, Florida, USA.,University of Central Florida College of Medicine, Orlando, Florida, USA
| |
Collapse
|
22
|
Gonzalez Catalan M, Paulraj S, Ma F, Arora S, Choi E, Gomez R. C - 04Neuropsychological Assessments for Adult Spanish Speakers in the United States. Arch Clin Neuropsychol 2018. [DOI: 10.1093/arclin/acy061.157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
Becker C, Choi E, Gonzalez Catalan M, Shin S, Arora S, Huddleson M, Gomez R. A - 25Executive Attention Predicts Agitation in Older Adults with Cognitive Impairment and Dementia. Arch Clin Neuropsychol 2018. [DOI: 10.1093/arclin/acy061.25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Arora S, Ordoñez C, Collins W, Gomez R. C - 12A Case of Accelerated Progression of Co-Morbid Primary Lateral Sclerosis and Frontotemporal Dementia. Arch Clin Neuropsychol 2018. [DOI: 10.1093/arclin/acy061.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Herazo-Maya F, Egurrola J, Restrepo CE, Torres L, Palacios L, Ossa CA, Borrero M, Angel GA, Marquez JJ, Valencia S, Perez A, Oyola JC, Lobo L, Gomez R, Garcia H. Abstract P5-22-04: Efficacy of thoracic paravertebral block for reducing acute post-mastectomy pain. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-22-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Mastectomy is associated with acute and chronic postoperative pain. This study investigated the efficacy of thoracic paravertebral block (TPB) compared to local anesthetic of surgical wound (LASW) in breast cancer patients undergoing mastectomy.
Methods: This phase 3, randomized controlled, single blind, parallel arms and superiority clinical trial aimed to evaluate the efficacy of TPB compared to LASW on acute pain at rest and motion at 24 hours post-mastectomy, measured by a visual analog scale (VAS). The study size of 60 patients is determined to have 90% power to detect a difference of 20% in acute pain in favor of TPB. In TPB group use of ultrasound was mandatory to guide puncture of intervertebral space T3 for infiltrating 0.5% bupivacaine at dose of 1.5 mg/kg. In LASW group was used bupivacaine 0.5% at dose of 1.5mg/kg on subcutaneous tissue of surgical area. VAS was used to measure surgical pain at rest and motion in 2,4,6,12 and 24 hours post-operatives for both groups. Trial Registry: ClinicalTrials.gov; Identifier:NCT02609321.
Findings: From 08-2015 to 09-2016, 60 breast cancer patients were enrolled; 3 dropped off consent. Mean age was 51 year; 78% had stage II and III; and 65% receive neoadjuvant chemotherapy.There were no significant differences in the VAS pain measurement for the groups of BWT compared to LASW in the 24 hour measurement, neither at rest (P=0.6525) nor in movement (P=0.7929). There were no significant differences in both groups for repeated pain measurements (5 measures mean), total dose of opioid administration, time to first dose of opioids or adverse events.
Conclusions: There were not statistical differences for post-mastectomy acute pain in first 24 hours between TPB and LASW patients. According our findings the use of TPB should not routinely recommended for breast cancer patients undergoing mastectomy.
Citation Format: Herazo-Maya F, Egurrola J, Restrepo CE, Torres L, Palacios L, Ossa CA, Borrero M, Angel GA, Marquez JJ, Valencia S, Perez A, Oyola JC, Lobo L, Gomez R, Garcia H. Efficacy of thoracic paravertebral block for reducing acute post-mastectomy pain [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-22-04.
Collapse
Affiliation(s)
- F Herazo-Maya
- Instituto de Cancerologia Clinica Las Americas, Medellin, Colombia; Clinica Las Americas, Medellin, Colombia; Universidad CES, Medellin, Colombia
| | - J Egurrola
- Instituto de Cancerologia Clinica Las Americas, Medellin, Colombia; Clinica Las Americas, Medellin, Colombia; Universidad CES, Medellin, Colombia
| | - CE Restrepo
- Instituto de Cancerologia Clinica Las Americas, Medellin, Colombia; Clinica Las Americas, Medellin, Colombia; Universidad CES, Medellin, Colombia
| | - L Torres
- Instituto de Cancerologia Clinica Las Americas, Medellin, Colombia; Clinica Las Americas, Medellin, Colombia; Universidad CES, Medellin, Colombia
| | - L Palacios
- Instituto de Cancerologia Clinica Las Americas, Medellin, Colombia; Clinica Las Americas, Medellin, Colombia; Universidad CES, Medellin, Colombia
| | - CA Ossa
- Instituto de Cancerologia Clinica Las Americas, Medellin, Colombia; Clinica Las Americas, Medellin, Colombia; Universidad CES, Medellin, Colombia
| | - M Borrero
- Instituto de Cancerologia Clinica Las Americas, Medellin, Colombia; Clinica Las Americas, Medellin, Colombia; Universidad CES, Medellin, Colombia
| | - GA Angel
- Instituto de Cancerologia Clinica Las Americas, Medellin, Colombia; Clinica Las Americas, Medellin, Colombia; Universidad CES, Medellin, Colombia
| | - JJ Marquez
- Instituto de Cancerologia Clinica Las Americas, Medellin, Colombia; Clinica Las Americas, Medellin, Colombia; Universidad CES, Medellin, Colombia
| | - S Valencia
- Instituto de Cancerologia Clinica Las Americas, Medellin, Colombia; Clinica Las Americas, Medellin, Colombia; Universidad CES, Medellin, Colombia
| | - A Perez
- Instituto de Cancerologia Clinica Las Americas, Medellin, Colombia; Clinica Las Americas, Medellin, Colombia; Universidad CES, Medellin, Colombia
| | - JC Oyola
- Instituto de Cancerologia Clinica Las Americas, Medellin, Colombia; Clinica Las Americas, Medellin, Colombia; Universidad CES, Medellin, Colombia
| | - L Lobo
- Instituto de Cancerologia Clinica Las Americas, Medellin, Colombia; Clinica Las Americas, Medellin, Colombia; Universidad CES, Medellin, Colombia
| | - R Gomez
- Instituto de Cancerologia Clinica Las Americas, Medellin, Colombia; Clinica Las Americas, Medellin, Colombia; Universidad CES, Medellin, Colombia
| | - H Garcia
- Instituto de Cancerologia Clinica Las Americas, Medellin, Colombia; Clinica Las Americas, Medellin, Colombia; Universidad CES, Medellin, Colombia
| |
Collapse
|
26
|
Gonzalez CM, Arora S, Gomez R. Diversity-3Neuropsychological Assessments for Adult Spanish Speakers in the United States. Arch Clin Neuropsychol 2017. [DOI: 10.1093/arclin/acx075.11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Paul N, Zenisek R, Becker M, Gomez R, Strong M, Chaleunsouck R, Allen D. C-76Psychometric Evaluation of a New Brief Test of Social Cognitive Abilities (BTSCA). Arch Clin Neuropsychol 2017. [DOI: 10.1093/arclin/acx076.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Milone G, Penna M, Fernandez F, Spitzer E, Millan S, Mariani S, Español N, Gomez R. PHARMOVIGILANCE OF RITUXIMAB BIOSIMILAR IN THE TREATMENT OF LYMPHOMAS IN ARGENTINA. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_195] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- G. Milone
- Hematology; Centro Medico Hematologico, Ciudad Autonoma de Buenos Aires; Argentina
| | - M.I. Penna
- Medical Affairs, Laboratorio ELEA SACIFyA, Ciudad Autonoma de Buenos Aires; Argentina
| | - F.A. Fernandez
- Pharmacovigilance, Laboratorio ELEA SACIFyA, Ciudad Autonoma de Buenos Aires; Argentina
| | - E. Spitzer
- Scientific Affairs, Laboratorio ELEA SACIFyA, Ciudad Autonoma de Buenos Aires; Argentina
| | - S. Millan
- Medical Direction, Mabxience; Madrid Spain
| | - S. Mariani
- Pharmacovigilance, Mabxience; Madrid Spain
| | - N. Español
- Pharmacovigilance, Mabxience; Madrid Spain
| | - R. Gomez
- Medical Affairs, Laboratorio ELEA SACIFyA, Ciudad Autonoma de Buenos Aires; Argentina
| |
Collapse
|
29
|
Bertin V, Bosch P, Del Angel G, Gomez R, Barbier J, Marécot P. Préparation de catalyseurs bimétalliques Pt-Au par réaction redox : caractérisation par diffraction et par diffusion centrale des rayons X. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/1995920120] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
30
|
Simon KC, Gomez R, Nadel L. 0234 LOSING MEMORIES WITH TARGETED MEMORY REACTIVATION. Sleep 2017. [DOI: 10.1093/sleepj/zsx050.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Bartels C, Gomez R, Schorsch M, Seufert R. Der prädiktive Wert des Time-lapse Imaging Systems für den Ausgang der In-vitro Fertilisation. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1593083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
32
|
Gomez R, Zier U, Passet-Wittig J, Seufert R, Münster E. Welche Rolle spielt der Gynäkologe als Ansprechpartner auf dem Weg in die Kinderwunschbehandlung? – Ergebnisse der Basiserhebung der prospektiven PinK-Studie (Paare in Kinderwunschbehandlung). Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
33
|
Macias AE, Ortiz R, Santiesteban E, Popa X, Zayas A, Mazorra Z, Mendoza I, Garcia E, Gomez R, Crombet T. P2.34: Vaxira and CIMAvax-EGF Therapeutic Vaccines Combination in the Advanced NSCLC Treatment. J Thorac Oncol 2016. [DOI: 10.1016/j.jtho.2016.08.105] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
34
|
Huddleson M, Jhingon G, Harley A, Shin S, Paulraj S, Gomez R. B-23The Bipolar Brain on Drugs: How Four Categories of Pharmaceuticals Affect Cognition in Euthymic Adult Patients with Bipolar Disorder. Arch Clin Neuropsychol 2016. [DOI: 10.1093/arclin/acw043.98] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
35
|
Posecion L, Jhingon G, Paulraj S, Nunan-Saah J, Duong P, Harley A, Van Moorleghem K, Conniff K, Huddleson M, Shin S, Keller J, Gomez R. B-20Executive Attention Predicts Verbal Memory in Major Depression. Arch Clin Neuropsychol 2016. [DOI: 10.1093/arclin/acw043.95] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Mayfield A, Lee B, Gomez R, Mayfield J, Allen D. C-25Neurocognitive Correlates of the Comprehensive Trail Making Test (CTMT) in Children with Neurological Disorders. Arch Clin Neuropsychol 2016. [DOI: 10.1093/arclin/acw043.174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Paulraj S, Harley A, Jhingon G, Duong P, Huddleson M, Shin S, Posecion L, Gomez R, Simone P, Haas A. A-06Wisconsin Card Sorting Test Performance in Healthy Older Adults Who Use Sudoku or Crossword Puzzles. Arch Clin Neuropsychol 2016. [DOI: 10.1093/arclin/acw043.06] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
38
|
Camposeco R, Castillo S, Navarrete J, Gomez R. Synthesis, characterization and photocatalytic activity of TiO2 nanostructures: Nanotubes, nanofibers, nanowires and nanoparticles. Catal Today 2016. [DOI: 10.1016/j.cattod.2015.09.018] [Citation(s) in RCA: 59] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
39
|
McCalmont K, Norris J, Garzon A, Cisneros R, Greene H, Regino L, Sandoval V, Gomez R, Page-Reeves J, Kaufman A. Community Health Workers and Family Medicine Resident Education: Addressing the Social Determinants of Health. Fam Med 2016; 48:260-264. [PMID: 27057603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Neither the health care system nor the training of medical residents focus sufficiently on social determinants of health. Community health workers (CHWs) are a growing presence in health care settings. Culturally and linguistically competent, typically they are from underserved communities and spend more time addressing social determinants of health than others on the health care team. However, CHWs are an infrequent presence in resident clinical training environments. The University of New Mexico Family Medicine Residency placed family medicine residents at a community clinic in Albuquerque managed by CHWs, recognizing that CHWs' collaboration with residents would enhance resident competency in multiple domains. Residents gained skills from CHWs in inter-professional teamwork, cultural proficiency in patient care, effective communication, provision of cost-conscious care, and advocating for both individual and community health. Our model recognizes the value of CHW skills and knowledge and creates a powerful rationale for greater recognition of CHW expertise and integration of CHWs as members of the care team.
Collapse
Affiliation(s)
- Kate McCalmont
- Department of Family and Community Medicine, University of New Mexico
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Hallums DP, Gomez R, Doyle AP, Viet CT, Schmidt BL, Jeske NA. RAF Kinase Inhibitory Protein Expression and Phosphorylation Profiles in Oral Cancers. Clin Surg 2016; 1:1100. [PMID: 28529999 PMCID: PMC5436720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Raf Kinase Inhibitory Protein (RKIP) expression has been profiled for a number of unique tissue cancers. However, certain tissues have not been explored, and oral and oropharyngeal cancers stand out as high priority targets, given their relatively high incidence, high morbidity rate, and in many cases, preventable nature. The purpose of this study was to examine changes in RKIP expression and phosphorylation in tissues resected from oral cancer patients, and compare to results generated from immortalized cell lines raised from primary oral cancer tissues, including oral squamous cell carcinoma line 4 (SCC4) and human squamous cell carcinoma line 3 (HSC3). Out of 4 human samples collected from male and female patients across various ages with variable risk factors, we observed an across the board reduction in RKIP expression. Two human samples demonstrated a significant increase in phosphorylated RKIP when normalized to total RKIP, however all 4 were increased when normalized to total cellular protein. The immortalized oral cancer cell culture HSC3 revealed significant increases in phosphorylated RKIP with no change in total RKIP expression, while line SCC4 demonstrated an increase in both total and phosphorylated RKIP. Results presented here indicate that oral cancers behave similarly to other cancers in terms of changes in RKIP expression and phosphorylation, although immortalized cell line expression profiles significantly differ from human tissue biopsies.
Collapse
Affiliation(s)
- DP Hallums
- Departments of Oral and Maxillofacial Surgery, University of Texas Health Science Center at San Antonio, USA
| | - R Gomez
- Departments of Oral and Maxillofacial Surgery, University of Texas Health Science Center at San Antonio, USA
| | - AP Doyle
- Departments of Pharmacology, University of Texas Health Science Center at San Antonio, USA
| | - CT Viet
- Department of Oral Maxillofacial Surgery, New York University, USA,Department of Oral Maxillofacial Surgery, Bluestone Center for Clinical Research, New York University, USA
| | - BL Schmidt
- Department of Oral Maxillofacial Surgery, New York University, USA,Department of Oral Maxillofacial Surgery, Bluestone Center for Clinical Research, New York University, USA
| | - NA Jeske
- Departments of Oral and Maxillofacial Surgery, University of Texas Health Science Center at San Antonio, USA,Departments of Pharmacology, University of Texas Health Science Center at San Antonio, USA,Departments of Physiology, University of Texas Health Science Center at San Antonio, USA,Correspondence: Nathaniel A. Jeske, Department of Oral & Maxillofacial Surgery, University of Texas Health Science Center of San Antonio, Center for Biomedical Neuroscience, 7703 Floyd Curl Dr., San Antonio, TX 78229-3900, USA, Tel: (210) 567-3466; Fax: (210) 567-2995;
| |
Collapse
|
41
|
Cannavo S, Bogazzi F, Colao A, De Marinis L, Maffei P, Gomez R, Graziano E, Monterubbianesi M, Grottoli S. Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience. J Endocrinol Invest 2015; 38:1099-109. [PMID: 25916431 DOI: 10.1007/s40618-015-0289-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2014] [Accepted: 04/09/2015] [Indexed: 12/13/2022]
Abstract
OBJECTIVE GH receptor antagonist pegvisomant is indicated for treatment of patients with resistant acromegaly. We compared safety and treatment outcomes of pegvisomant therapy in patients managed by Italian centers enrolling less or more than 15 cases in ACROSTUDY, a safety surveillance study of long-term pegvisomant treatment of patients with acromegaly. A noninterventional safety surveillance study in which safety and treatment outcomes of pegvisomant were evaluated on the basis of data collected during a 7-year period. METHODS A total of 204 acromegaly patients treated by seven centers enrolling 16-49 patients each (group A) and 137 subjects by 18 centers following 3-14 cases ( group B). RESULTS Patients of group A and B were treated for 4.4 ± 2.7 and 4.2 ± 2.2 years, respectively. IGF-1 ULN normalized in 64.4 % (n = 56) and 54.4 % (n = 31) in group A and B, respectively, after 1-year treatment, and in 57.3 % (n = 106) and 72.5 % (n = 87) at last visit. Starting doses were significantly higher in group A. They were progressively increased during treatment in both groups, but were higher in uncontrolled patients than in controlled ones only in group A. Reported adverse events were more frequent, and the prevalence of patients with adverse events was higher in group B. CONCLUSIONS On the basis of this original study approach, we could speculate that in the centers in which more patients are treated with pegvisomant, less adverse events are reported, but the long-term effectiveness is lower than in centers with less cases, perhaps because of an inadequate patient's selection.
Collapse
Affiliation(s)
- S Cannavo
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| | - F Bogazzi
- Department of Endocrinology and Metabolic Diseases, Ospedale Cisanello, Pisa, Italy
| | - A Colao
- Endocrinological Clinic, Departmeno of Endocrinology and Molecular and Clinic Oncology, Policlinico Universitario Federico II, Naples, Italy
| | - L De Marinis
- Institute of Endocrinology, Cattolica del Sacro Cuore University, Policlinico A. Gemelli, Rome, Italy
| | - P Maffei
- III Medical Clinic, Department of Medicine, Azienda Ospedaliera di Padova, Padua, Italy
| | - R Gomez
- Pfizer Europe Medical Affairs, Endocrinology, Puurs, Belgium
| | - E Graziano
- Pfizer Italia, Medical Department Endocrinology, Rome, Italy
| | | | - S Grottoli
- Department of Medicine, Division of Endocrinology, Diabetology and Metabolism, Città della, Salute e della Scienza di Torino, University of Torino, Turin, Italy.
| |
Collapse
|
42
|
Ysa A, Lobato M, Gomez R, Arruabarrena A, Metcalfe M, Fonseca JL. Reply: To PMID 24797552. J Vasc Surg 2015; 62:1103-4. [PMID: 26410053 DOI: 10.1016/j.jvs.2015.03.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2015] [Accepted: 03/14/2015] [Indexed: 10/23/2022]
Affiliation(s)
- August Ysa
- Vascular Surgery Department, Hospital de Cruces, Barakaldo, Spain
| | - Marta Lobato
- Vascular Surgery Department, Hospital de Cruces, Barakaldo, Spain
| | - Roberto Gomez
- Vascular Surgery Department, Hospital de Cruces, Barakaldo, Spain
| | | | - Matthew Metcalfe
- Vascular Surgery Department, Lister Hospital, Stevenage, United Kingdom
| | | |
Collapse
|
43
|
Staffaroni A, Gomez R, Trettin L, Schatzberg A, Katznelson L, Keller J. A-16The Cognitive Profiles of Cushing's Disease and Psychotic Major Depression. Arch Clin Neuropsychol 2015. [DOI: 10.1093/arclin/acv047.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Conniff K, van Moorleghem K, Gill S, Posecion L, Coopersmith L, Nunan-Saah J, Paulraj S, Gomez R. B-25Can Depression Predict Functional Impairment in Lewy Body Dementia? Arch Clin Neuropsychol 2015. [DOI: 10.1093/arclin/acv047.121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
Gomez R, Buchholz S, Suikkanen H. Experimental and numerical investigation of heat transfer and pressure drop for innovative gas cooled systems. Nuclear Engineering and Design 2015. [DOI: 10.1016/j.nucengdes.2014.11.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
46
|
Garcia-Mora P, Peñas E, Frias J, Gomez R, Martinez-Villaluenga C. High-pressure improves enzymatic proteolysis and the release of peptides with angiotensin I converting enzyme inhibitory and antioxidant activities from lentil proteins. Food Chem 2015; 171:224-32. [DOI: 10.1016/j.foodchem.2014.08.116] [Citation(s) in RCA: 105] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2014] [Revised: 07/11/2014] [Accepted: 08/26/2014] [Indexed: 01/02/2023]
|
47
|
Grottoli S, Maffei P, Bogazzi F, Cannavò S, Colao A, Ghigo E, Gomez R, Graziano E, Monterubbianesi M, Jonsson P, De Marinis L. ACROSTUDY: the Italian experience. Endocrine 2015; 48:334-41. [PMID: 25150035 DOI: 10.1007/s12020-014-0393-9] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2014] [Accepted: 08/11/2014] [Indexed: 11/28/2022]
Abstract
ACROSTUDY is a world-wide non-interventional, post marketing surveillance study performed to monitor the safety and outcomes of pegvisomant (PEG) in clinical practice. We report data from acromegaly patients who have been included in the Italian ACROSTUDY registry. The data of 341 acromegaly patients (171 males) were available for analysis using data freeze (12/9/2012). Patients were enrolled in 25 Italian endocrine centres. Before and during PEG treatment IGF-I, liver enzymes, metabolic parameters, and pituitary MRI were assessed. Before PEG, 54.3% patients had been treated with medical therapy and surgery, 22.9% medical therapy only, and 15.8% medical plus radiation and surgical therapy. 199 adverse events were reported in 98 patients (28.7%). Serious adverse events were documented in 29 patients (8.5%). 71.1% of patients had no significant change in tumor volume. Central MRI reading was performed in 34 patients; in 7 patients, an increase in tumor volume was found. Hormonal efficacy progressively increased since the start of PEG. After 6 years, normal IGF-I levels were found in 70.9% of patients (mean daily dose 18.1 mg). 87.1% of patients were treated with daily PEG although in 8.8% of patients, it was administered 2-6 times per week and in 3.8% with weekly injections. 74.8% received a PEG dose 10-15 mg/daily. PEG is a drug with a favorable safety profile which is efficacious also considering that in Italy it is currently available as third-line therapy.
Collapse
Affiliation(s)
- S Grottoli
- Divisione di Endocrinologia, Diabetologia e Metabolismo, Dipartimento di Scienze Mediche, AO Città della Salute e della Scienza di Torino, Università di Torino, C.so AM Dogliotti 14, 10126, Turin, Italy,
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Gomez R, Schorsch M, Hahn T, Henke A, Hoffmann I, Seufert R, Skala C. The influence of AMH on IVF/ICSI success. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1387989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
49
|
Gomez R, Görg C, Bockmeyer K, Seufert R, Skala C. Höhergradige Mehrlinge: ein Problem der Reproduktionsmedizin? Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
50
|
Bockmeyer K, Gomez R, Görg MC, Schorsch M, Seufert R. Konzeptionsmodus bei höhergradigen Mehrlingen; Erfahrungen aus 30 Jahren an der Frauenklinik Mainz. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|